Over the years, as Sanofi and Regeneron’s Dupixent racked up new indications and approached the French pharma giant’s 10 billion euro peak sales goal, analysts had started …
Sanofi and Regeneron have big ambitions for immunology superstar Dupixent—envisioning the potential for $11 billion in annual sales. In acing a test in people with …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
